IDRA Key Stats
|Revenue (Quarterly YoY Growth)||133.3%|
|EPS Diluted (TTM)||-0.6462|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-15.93M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-67686%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- 4 Health Care Stocks Under $10 to Watch The Street Dec 11
- Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenström’s Macroglobulinemia noodls Dec 4
- Idera Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference noodls Nov 25
- IDERA PHARMACEUTICALS, INC. Financials Nov 20
- Idera Pharmaceuticals, Inc. Earnings Call scheduled for 8:30 am ET today Nov 14
- Idera Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Corporate Update noodls Nov 14
- Idera Pharmaceuticals, Inc. (IDRA) Reports In-Line Q3 Loss of 11c/Share Street Insider Nov 14
- IDERA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 14
- Q3 2013 Idera Pharmaceuticals, Inc. Earnings Release - Time Not Supplied Nov 13
- Idera Pharmaceuticals to Host Conference Call to Report Third Quarter 2013 Financial Results on Thursday, November 14, 2013 noodls Nov 7
IDRA Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Idera Pharmaceuticals is up 304.4% over the last year vs S&P 500 Total Return up 28.99%, Amgen up 28.32%, and Alcobra up N/A.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for IDRA
Pro Strategies Featuring IDRA
Did Idera Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Idera Pharmaceuticals, Inc., is a clinical stage biotechnology company engaged in the discovery and development of novel synthetic DNA- and RNA- based drug candidates.